Targeted nanoparticles for treating pancreatic cancer
Stimuli-responsive mucin1-specific nanoparticles for efficacious combinatorial chemotherapy of pancreatic ductal adenocarcinoma
This study is working on tiny particles that can deliver chemotherapy directly to pancreatic cancer cells, making the treatment more effective and helping patients get better results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Carolina Charlotte NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project ID | NIH-10903807 on NIH RePORTER |
What this research studies
This research focuses on developing nanoparticles that specifically target pancreatic ductal adenocarcinoma (PDAC) cells to deliver chemotherapy drugs more effectively. By using a stimuli-responsive system, the nanoparticles can release the drugs, cisplatin and gemcitabine, directly at the tumor site, potentially overcoming the resistance that PDAC has to traditional therapies. The approach aims to improve the bioavailability and distribution of these drugs, which could lead to better treatment outcomes for patients with this aggressive cancer. The research involves synthesizing and characterizing these nanoparticles to ensure they effectively target the cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment efficacy and survival rates for patients with pancreatic cancer.
How similar studies have performed: Other research has shown promise in using targeted drug delivery systems for cancer treatment, indicating that this approach could be effective.
Where this research is happening
Charlotte, United States
- University of North Carolina Charlotte — Charlotte, United States (Active)
Researchers
- Principal investigator: Vivero-Escoto, Juan Luis — University of North Carolina Charlotte
- Study coordinator: Vivero-Escoto, Juan Luis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.